Table II.
Expression of immune checkpoint molecules on CD8+ T cells in malignant ascites from ovarian carcinoma.
| Characteristcs | High PD-1/total (%) | P-value | High LAG-3/total (%) | P-value | High TIM-3/total (%) | P-value | High BTLA/total (%) | P-value |
|---|---|---|---|---|---|---|---|---|
| Age (years) | ||||||||
| ≥65 | 13/25 (52.0) | 0.78 | 13/25 (52.0) | 0.78 | 13/25 (52.0) | 0.78 | 12/25 (48.0) | 0.78 |
| ≤64 | 14/29 (48.3) | 14/29 (48.3) | 14/29 (48.3) | 15/29 (51.7) | ||||
| FIGO stage | ||||||||
| I + II | 6/8 (75.0) | 0.13 | 5/8 (62.5) | 0.44 | 3/8 (37.5) | 0.44 | 3/8 (37.5) | 0.44 |
| III + IV | 21/46 (45.7) | 22/46 (47.8) | 24/46 (52.2) | 24/46 (52.2) | ||||
| Histology | ||||||||
| Serous | 18/31 (58.1) | 0.51 | 15/31 (48.4) | 0.85 | 19/31 (61.3) | 0.29 | 19/31 (61.3) | 0.18 |
| Clear cell | 3/8 (37.5) | 4/8 (50.0) | 3/8 (37.5) | 3/8 (37.5) | ||||
| Endometrioid | 3/6 (50.0) | 4/6 (66.7) | 2/6 (33.3) | 3/6 (50.0) | ||||
| Others | 3/9 (33.3) | 4/9 (44.4) | 3/9 (33.3) | 2/9 (22.2) | ||||
| Type | ||||||||
| I | 7/13 (53.8) | 0.75 | 7/13 (53.8) | 0.75 | 3/13 (23.1) | 0.03a | 4/13 (30.8) | 0.11 |
| II | 20/41 (48.8) | 20/41 (48.8) | 24/41 (58.5) | 23/41 (56.1) |
PD-1, programmed cell death protein-1; LAG-3, lymphocyte-activation gene-3; TIM-3, T-cell immunoglobulin and mucin-domain containing-3; BTLA, B and T lymphocyte attenuator; FIGO, International Federation of Gynecology and Obstetrics.